Botulinum toxin type A for aging face and aesthetic uses

Dermatologic Therapy

Volumn 24, Issue 1, 2011, Pages 54-61

  Hexsel, Camile ^a   Hexsel, Doris ^b   Porto, Manoela Donida ^b   Schilling, Juliana ^b   Siega, Carolina ^b,c  

^a HENRY FORD HOSPITAL   (United States)

^b Brazilian Center for Studies in Dermatology   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

aesthetic procedures; aging face; botulinum toxin; clinical practice; rejuvenation

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; CHIN; CLINICAL EVALUATION; CUTANEOUS PARAMETERS; ESTHETICS; FACE; FACE PROFILE; FACIAL EXPRESSION; FOREHEAD; HUMAN; LOWER EYELID; PLATYSMA MUSCLE; TREATMENT INDICATION; WRINKLE;

AMBULATORY CARE; BOTULINUM TOXINS, TYPE A; COSMETIC TECHNIQUES; ESTHETICS; FACE; FEMALE; HUMANS; MALE; SKIN AGING; TREATMENT OUTCOME;

EID: 79551551167     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01378.x     Document Type: Article

References (43)

1. Carruthers J, Carruthers A,. Botulinum toxin in facial rejuvenation: an update. Dermatol Clin 2009: 27 (4): 417-425; v. Review.
2. Brandt F, Swanson N, Baumann L, Huber B,. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009: 35 (12): 1893-1901.
3. Hexsel D, Hexsel CL,. Botulinum toxins. In:, Robinson JK, Hanke CW, Siegel DM, Fratila A, eds. Surgery of the skin-procedural dermatology, 2nd ed. Edinburgh, UK: Elsevier, 2010: 433-446.
4. Wu Y, Zhao G, Li H, et al. Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2010: 36 (1): 102-108.
5. Ascher B, Rzany BJ, Grover R,. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 2009: 35 (10): 1478-1486.
6. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M,. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006: 13 (Suppl. 4): 35-40. Review.
7. Kim WO, Kil HK, Yoon KB, Noh KU,. Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk. Dermatol Surg 2009: 35 (5): 833-838; discussion 838.
8. Benedetto AV,. Asymmetrical smiles corrected by botulinum toxin serotype A. Dermatol Surg 2007: 33 (1 Spec No.): S32-S36.
9. Carruthers JD, Glogau RG, Blitzer A, Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies-consensus recommendations. Plast Reconstr Surg 2008: 121 (5 Suppl.): 5S-30S; quiz 31S-36S.
10. Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood unit)-part I: upper facial wrinkles. J Eur Acad Dermatol Venereol 2010: 24 (11): 1278-1284.
11. Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood unit)-part II: wrinkles on the middle and lower face, neck and chest. J Eur Acad Dermatol Venereol 2010: 24 (11): 1285-1295.
12. Sattler G,. Patient management and treatment technique. Clin Dermatol 2003: 21: 485-487.
13. Pena MA, Alam M, Yoo SS,. Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis. Semin Cutan Med Surg 2007: 26 (1): 29-33.
14. Weiss RA, Lavin PT,. Reduction of pain and anxiety prior to botulinum toxin injections with a new topical anesthetic method. Ophthal Plast Reconstr Surg 2009: 25 (3): 173-177.
15. Wollina U, Konrad H,. Managing adverse events associated with botulinum toxin type-A: a focus on cosmetic procedures. Am J Clin Dermatol 2005: 6 (3): 141-150.
16. Hexsel DM, Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003: 29: 523-529.
17. Hexsel D, Alencar de Castro I, Zechmeister D, Almeida do Amaral A,. Re: Hexsel et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin a reconstituted up to six consecutive weeks before application. Dermatol Surg 2004: 30: 823.
18. Hexsel D, Rutowitsch M, Castro LC, do Prado DZ, Lima MM,. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of botulinum toxin type A reconstituted up to 15 days before injection. Dermatol Surg 2009: 35: 933-939.
19. Karsai S, Raulin C,. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 2009: 35 (1): 1-8.
20. Karsai S, Raulin C,. Do different formulations of botulinum toxin type A really have different migration characteristics? J Cosmet Dermatol 2008: 7 (3): 230.
21. Hexsel D, Dal'Forno T, Hexsel C, Do Prado DZ, Lima MM,. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg 2008: 34 (1): 52-59.
22. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002: 46: 840-849.
23. Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J,. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004: 51: 223-233.
24. Monheit G, Carruthers A, Brandt F, Rand R,. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007: 33 (Suppl. 1): 51-59.
25. Karsai S, Raulin C,. Botox and Dysport: is there a dose conversion ratio in dermatology and aesthetic medicine? J Am Acad Dermatol 2010: 62 (2): 346-347.
26. Price KM, Williams ZY, Woodward JA,. Needle preference in patients receiving cosmetic botulinum toxin type A. Dermatol Surg 2010: 36 (1): 109-112.
27. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W,. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006: 142 (3): 320-326.
28. Benedetto A,. The cosmetic uses of botulinum toxin type A. Int J Dermatol 1999: 38: 641-655. (Pubitemid 29468703)
29. Hexsel DM, Klein A,. Botulinum toxin. In:, Baran R, Maibach HI, eds. Textbook of cosmetic dermatology, 3rd ed. New York, NY: Martin Dunitz Publisher-Group Taylor & Francis, 2005: 707-717.
30. Carruthers A, Carruthers J,. Eyebrow height after botulinum toxin type A to the glabella. Dermatol Surg 2007: 33 (1 Spec No.): S26-S31.
31. Hexsel D, Hexsel C, Zechmeister-Prado D,. Botulium toxins. In:, Saltz R, ed. Cosmetic medicine and aesthetic surgery. Strategies for success. Saint Louis, MO: Quality Medical Publishing Inc., 2009: 285-309.
32. Klein AW,. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 2004: 22: 66-75.
33. Carruthers A,. Botulinum toxin type A: history and current cosmetic use in the upper face. Dis Mon 2002: 48 (5): 299-322.
34. Hexsel D, Mazzuco R, Zechmeister M, Hexsel CL,. Complications and adverse effects: diagnosis and treatment. In:, Hexsel DM, Almeida AT, eds. Cosmetic use of botulinum toxin. Porto Alegre, Brazil: AGE, 2002: 233-239.
35. Carruthers J, Carruthers A,. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg 2003: 29: 468-476. (Pubitemid 36583143)
36. Flynn TC, Carruthers J, Carruthers A,. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 2001: 27 (8): 703-708.
37. Carruthers J, Carruthers A,. The adjunctive usage of botulinum toxin. Dermatol Surg 1998: 24: 1244.
38. Mazzuco R,. Perioral wrinkles. In:, Hexsel D, Almeida AT, eds. Cosmetic use of botulinum toxin. Porto Alegre, Brazil: AGE, 2002: 158-263.
39. Carruthers J, Fagien S, Matarasso SL, Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in face aesthetics. Plast Reconstr Surg 2004: 114 (Suppl. 6): 1S-22S.
40. Coscarelli JM,. Gingival smile: a new technique as an aesthetic solution. In:, Hexsel D, Almeida AT, eds. Cosmetic use of botulinum toxin. Porto Alegre, Brazil: AGE, 2002: 198-200.
41. De Sa Earp AP, Marmur ES,. The five D's of botulinum toxin: doses, dilution, diffusion, duration and dogma. J Cosmet Laser Ther 2008: 10 (2): 93-102.
42. Becker-Wegerich PM, Rauch L, Ruzicka T,. Botulinum toxin A: successful décolleté rejuvenation. Dermatol Surg 2002: 28: 168-171.
43. Isaac C, Gimenez R, Ruiz RO,. Breast wrinkles (décolleté folds). In:, Hexsel D, Almeida AT, eds. Cosmetic use of botulinum toxin. Porto Alegre, Brazil: AGE, 2002: 178-181.